Ronika Alexander-Parrish (L), Pfizer vaccines clinical scientist and founding director of its DrPH at Morgan State, and Monica Ochapa, one of the inaugural Pfizer fellows

August 25, 2022 02:11 PM EDTUpdated 03:21 PM

Marketing

Pfizer teams with historically Black university for new vaccine public health doctorate program

Beth Snyder Bulik

Senior Editor

Monica Ochapa is in her third year pursuing a doctorate of public health at the historically black university Morgan State — and one of two first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer teams with historically Black university for new vaccine public health doctorate program

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Pfiz­er teams with his­tor­i­cal­ly Black uni­ver­si­ty for new vac­cine pub­lic health doc­tor­ate pro­gram

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Pfizer teams with historically Black university for new vaccine public health doctorate program

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?